Deutsche Bank AG reaffirmed their buy rating on shares of Shire PLC (LON:SHP) in a report published on Wednesday morning. The firm currently has a GBX 6,200 ($76.73) price objective on the biopharmaceutical company’s stock.
SHP has been the topic of a number of other research reports. JPMorgan Chase & Co. reissued an overweight rating and issued a GBX 6,300 ($77.97) target price on shares of Shire PLC in a report on Tuesday, August 16th. BNP Paribas reissued an outperform rating and issued a GBX 5,700 ($70.54) target price on shares of Shire PLC in a report on Wednesday, June 15th. Jefferies Group raised their target price on shares of Shire PLC from GBX 6,050 ($74.88) to GBX 6,600 ($81.68) and gave the stock a buy rating in a report on Wednesday, August 3rd. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a report on Friday, July 22nd. Finally, Shore Capital reissued a buy rating on shares of Shire PLC in a report on Tuesday, August 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of GBX 5,841.33 ($72.29).
Shares of Shire PLC (LON:SHP) opened at 5087.00 on Wednesday. The firm’s market cap is GBX 34.73 billion. The company has a 50 day moving average price of GBX 4,998.05 and a 200-day moving average price of GBX 4,592.96. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00.
The business also recently announced a dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 8th were paid a dividend of GBX 3.51 ($0.04) per share. This represents a dividend yield of 0.07%. The ex-dividend date was Thursday, September 8th.
In other Shire PLC news, insider Dominic Blakemore acquired 133 shares of Shire PLC stock in a transaction that occurred on Friday, September 30th. The stock was acquired at an average price of GBX 5,010 ($62.00) per share, with a total value of £6,663.30 ($8,246.66).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.